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Carcinoma of unknown primary site (CUP) is rarely encountered in clinical practice and optimal chemotherapy has not yet been
established. This phase II study was conducted to evaluate the efficacy and toxicity of combined irinotecanþcarboplatin therapy in
chemotherapy-naive patients with CUP. Irinotecan was administered at 60mgm
 2 as a 90-min intravenous infusion on days 1, 8 and
15. Carboplatin was administered at an area-under-the curve of 5mgml
 1min as a 60-min intravenous infusion on day 1. This cycle
was repeated every 28 days for up to six cycles. Forty-five patients were enrolled in the study. An intent-to-treat analysis revealed an
objective response rate to the treatment of 41.9% (95% confidence interval, 27.0–57.9%). The median time to progression was 4.8
months and the median survival was 12.2 months. The 1- and 2-year survival rates were 44 and 27%, respectively. The most frequent
grade 3 or more severe adverse events were leukopaenia (21%), neutropaenia (33%), anaemia (25%) and thrombocytopaenia (20%).
Thus, the combination of irinotecan plus carboplatin was found to be active in patients with CUP. Therefore, the regimen may be one
of the potentially available chemotherapeutic options for community standard of care in patients with a good performance status.
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Carcinoma of unknown primary site (CUP) represents a group of
heterogeneous malignancies that is diagnosed based on the
presence of a metastatic disease without an identifiable primary
tumour at the time of presentation. Carcinoma of unknown
primary site accounts for approximately 3–5% of all newly
diagnosed patients with malignancies (Briasoulis et al, 2008b).
The prognosis of CUP is generally poor, with a median overall
survival time (OS) of approximately 6–12 months. Some of these
patients with favourable and unique clinical and/or pathologic
features may show prolonged survival with specific treatment
approaches (Pavlidis et al, 2003). However, most of the patients fit
into the category of poor prognosis. Many investigators have made
efforts to develop optimal chemotherapeutic regimens based on
the empiric approach, and platinum-based combination chemo-
therapy is considered to be one of the suitable treatment options
for a large proportion of these patients (Pavlidis et al, 2003).
Irinotecan is a potent inhibitor of DNA topoisomerase I. It
exhibits excellent antitumour activity, not only against a broad
spectrum of tumours in experimental models (Kano et al, 1992;
Misawa et al, 1995). Carboplatin is an analogue of cisplatin, with
less severe non-haematological toxicities (Briasoulis et al, 2000;
Yonemori et al, 2005). No cross-resistance has been found between
irinotecan and carboplatin, and a synergistic effect of irinotecan
with carboplatin has been shown in in vitro studies (Kano et al,
1993).
In an earlier study conducted by us, although the combination
of docetaxel plus cisplatin produced favourable results in patients
with CUP, treatment discontinuation sometimes became necessary
because of the renal toxicity induced by cisplatin (Mukai et al,
2003; Yakushiji et al, 2006). Carboplatin has proven to be as
effective as cisplatin against chemosensitive CUP, with an
additional advantage of being better tolerated and more con-
venient in clinical practice (Briasoulis et al, 2000). In this study, we
report the results of a phase II trial conducted to evaluate the effect
of irinotecan plus carboplatin in the treatment for CUP.
PATIENTS AND METHODS
Patients
Patients who had histologically confirmed metastatic carcinoma
were eligible for enrollment in this study, if the following
evaluations did not reveal a primary site: complete history,
physical examination, blood counts and blood chemistry examina-
tions, including serum a-fetoprotein (AFP) and b-human
chorionic gonadotropin (b-HCG) as tumour markers in both
sexes, carbohydrate antigen 125 (CA125) as a tumour marker in
women, prostate-specific antigen (PSA) as a tumour marker in
men, urinalysis, head and neck examination with pharyngeal
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sendoscopy conducted by experienced head and neck surgeons,
urologic examination conducted by experienced urologists,
mammography in women, gynaecologic examination by experi-
enced gynaecologists in women, chest X-ray, whole-body
computed tomography, upper gastrointestinal endoscopy, lower
gastrointestinal endoscopy or barium enema, bone scintigraphy
and direct workup of any symptomatic area.
Patients were enrolled in the study if they fulfilled the following
eligibility criteria: (1) diagnosed as having CUP, (2) chemotherapy
naive, (3) ageX20 years, (4) life expectancy of at least 3 months,
(5) an Eastern Cooperative Oncology Group performance status of
p2, (6) the presence of a measurable lesion as assessed by
Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse
et al, 2000) and (7) adequate organ function (total leukocyte
countX3000 per ml or absolute neutrophil countX1500 per ml,
platelet countX100000 per ml, serum total bilirubinp1.5mgdl
 1,
serum alanine aminotransferasep2 times the upper limit of
normal, serum creatininep1.5mgdl
 1). Patients with active
infection, bowel obstruction, interstitial pneumonitis, uncontrolled
severe heart disease, uncontrolled diabetes mellitus, pregnant or
lactating women, symptomatic brain metastasis, severe coexistent
medical illness or a past history of hypersensitivity to drugs were
excluded from the study. Patients who had massive pleural
effusion or ascites that required drainage or active concomitant
malignancy were also excluded. Patient subgroups that were
suitable for well-established treatments (i.e., men with blastic bone
metastases showing features of adenocarcinoma and elevated PSA,
women with axillary lymph nodes as the only site of disease
showing features of adenocarcinoma, woman with papillary serous
carcinoma of the peritoneum, patients with either cervical or
inguinal lymph node involvement only with features of squamous
cell carcinoma, patients with poorly differentiated carcinomas
suggestive of germ cell tumour with elevated levels of AFP and/or
b-HCG, patients with low-grade, well-differentiated neuroendo-
crine carcinoma and patients with carcinoma involving a single,
potentially resectable site) were also excluded from the study.
The protocol was approved by the institutional review board.
All patients provided written informed consent before their
enrollment.
Treatment
Irinotecan was administered at the dose of 60mgm
 2 dissolved in
100ml saline as a 90-min intravenous infusion, followed by
carboplatin at an area-under-the curve of 5mgml
 1min dissolved
in 250ml of saline or 5% dextrose as a 60-min intravenous
infusion. Irinotecan administration was planned for days 1, 8 and
15 of each cycle, and that of carboplatin was planned for day 1 of
each cycle. The Calvert formula was used to determine the
carboplatin dose, based on the glomerular filtration rate calculated
using the serum creatinine level, body weight, age and sex
(Cockcroft and Gault, 1976; Calvert et al, 1989). Patients showing
treatment response or stable disease were administered up to a
total of six courses. Granisetron 3mg and dexamethasone 8mg
were used routinely before the drug infusions as antiemetic agents
on days 1, 8 and 15. Prophylactic granulocyte colony-stimulating
factor was not used routinely.
Irinotecan and carboplatin were administered on day 1 if the
leukocyte count was X3000 per ml or the neutrophil count was
X1500 per ml, the platelet count was X75000 per ml, serum total
bilirubin was p1.5mgdl
 1, serum alanine aminotransferase was
p2 times the upper limit of normal, the serum creatinine was
p1.5mgdl
 1 and any non-haematological toxicities, with the
exception of alopaecia, were pgrade 1. Patients who failed to
improve to less than grade 2 in terms of the non-haematological
toxicity even after withholding of the treatment for 2 weeks were
withdrawn from the study.
Irinotecan was administered on day 8 or 15 if the leukocyte
count was X2000 per ml or the neutrophil count was X1000 per ml,
the platelet count was X75000 per ml and any non-haematological
toxicities, with the exception of alopaecia, were pgrade 1. The
dose on day 8 and/or day 15 was omitted entirely if the counts or
toxicities did not satisfy the above criteria.
Dose modification of carboplatin from AUC 4 to AUC 5 was
allowed if febrile neutropaenia or grade 4 thrombocytopaenia was
observed, or if platelet transfusion was required.
Response and toxicity evaluation
All patients were re-evaluated for response after completion of two
cycles of treatment, and the response categories were assigned
based on the RECIST criteria (Therasse et al, 2000). Repeat scans
at 8-week intervals were performed to confirm the response. The
final response category assigned to these patients represented the
best response obtained during the treatment course. Toxicities
were evaluated according to the National Cancer Institute’s
Common Toxicity Criteria, Version 2.0, after every cycle and at
the end of the study treatment.
Statistical analysis
The primary end point of this study was the objective response
rate, defined as the proportion of patients with complete response
or partial response in the intent-to-treat (ITT) population, in turn,
defined as patients who had received at least one cycle of
irinotecan and carboplatin. The secondary end points included
safety and tolerability, time to tumour progression (TTP), OS, and
the 1- and 2-year survival rates.
The sample size was determined using Simon’s Minimax
two-stage design for phase II studies. The response rates to
chemotherapy of patients with CUP have been reported as
approximately in the range of 20–40% (Briasoulis et al, 2000;
Greco et al, 2000a,b; Dowell et al, 2001), so that the null hypothesis
was that the true response rate was less than or equal to 30% (not
considered to be clinically meaningful). The alternative hypothesis
was that the true response rate was more than or equal to 50%. A
total of 39 patients were required as the target sample to ensure
results with 80% power and a type I error rate of 5%, for rejecting
the null hypothesis that the true response probability was less than
or equal to 30%. The enrollment of 45 patients was planned to
fulfill the requirement of 39 patients, because some patients might
need to be potentially excluded from the analysis because of failure
to receive at least one cycle of irinotecan and carboplatin.
The objective response rate was reported as a percentage, along
with the 95% confidence interval. The TTP and OS were
determined by the Kaplan–Meier method. All the statistical
analyses were performed using SPSS 12.0J (SPSS Inc., Chicago,
IL, USA).
RESULTS
Patient characteristics
Between May 2003 and November 2007, 45 patients were enrolled
in this clinical trial. The patient characteristics are listed in Table 1.
The median age was 59 years (range, 36–78 years), and the median
performance status (PS) was 1 (range, 0–2). The median number
of disease sites per patient was two (range, 1–7).
Twenty-three patients had lymph node involvement only. Serum
tumour markers were assessed at the baseline pretreatment
evaluation in 43 patients. The median number of tumour markers
showing elevated serum levels was 5 (range, 0–10). Eighty-seven
percent (N¼39) of the patients showed elevated serum levels of
tumour markers at the time of diagnosis (Table 2).
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Forty-five patients were enrolled in this study. All the enrolled
patients were included in the analysis for TTP and OS, and 43
patients who had received at least one cycle of irinotecan plus
carboplatin were assessed for tumour response to treatment. Two
patients who were withdrawn from the study because of the
appearance of toxicity in cycle 1 were considered as not evaluable.
Objective response was observed in 18 patients, including
complete response in two and partial response in 16 patients.
Stable disease was observed in 10 patients and progressive disease
in 15 patients. The results of an ITT analysis revealed an objective
response rate of 41.9% (95% confidence interval, 27.0–57.9%); the
response rate was 41.3% in the 30 patients with well-to-poorly
differentiated adenocarcinoma and 50.0% in the 23 patients with
lymph node involvement only. The median TTP was 4.8 months,
and the median OS was 12.2 months. The 1- and 2-year survival
rates were 44 and 27%, respectively (Figure 1).
Toxicity
The toxicity data are listed in Table 3. Bone marrow suppression
(leukopaenia, neutropaenia and thrombocytopaenia) and gastro-
intestinal toxicities, such as nausea, vomiting, diarrhoea and
appetite loss, were the most frequent. There were no treatment-
related deaths in this study.
Overall, 180 treatment cycles were administered and the median
number of cycles per patient was four (range, 1–6). Of the 180
cycles, in 9.4% (17 episodes), the day-8 administration of
irinotecan was withheld because of neutropaenia (11.8%), anaemia
(5.9%), thrombocytopaenia (35.3%) or non-haematological toxi-
city (41.1%), including two episodes of fatigue, three episodes of
nausea, two episodes of infection and one episode of palpitation.
Furthermore, in 27.2% of the cycles, the day-15 administration
of irinotecan was withheld because of neutropaenia (14.3%),
thrombocytopaenia (65.3%), non-haematological toxicity (16.3%),
including one episode of appetite loss, one episode of nausea, two
episodes of diarrhoea, four episodes of febrile neutropaenia and
patient refusal for personal reasons (two instances). The day-8 or
day-15 irinotecan was withheld at least once in 24 (53%) patients.
Five patients (11.1%) with anaemia required red blood cell
transfusion and four patients (8.9%) with thrombocytopaenia
required platelet transfusion. Dose modification of carboplatin was
necessary in 15.5% of the patients (seven patients).
DISCUSSION
Recently published trials, in the literature, of regimens containing
platinum agents for CUP have reported objective response rates in
the range of 13–55% and median OS in the range of 6.0–16.2
Table 1 Patient characteristics
Characteristics No. of patients
No. of patients enrolled 45
Age (years)
Median 59
Range 36–78
Sex
Male 23
Female 22
ECOG performance status
01 9
12 2
24
Histologic type
Adenocarcinoma (well and moderately differentiated) 21
Poorly differentiated adenocarcinoma 9
Squamous cell carcinoma 7
Poorly differentiated carcinoma 5
Clear cell carcinoma 1
Small cell carcinoma 1
Undifferentiated carcinoma 1
No. of disease sites
11 3
21 0
X32 2
Site of disease
Lymph node 40
Lung 6
Bone 4
Liver 8
Adrenal 2
Malignant effusion 4
Soft tissue 3
Other 6
Prognostic index
Culine et al (2002a)
a
Good risk 29
Poor risk 16
van der Gaast et al (1996)
b
Good risk 19
Intermediate risk 19
Poor risk 7
ECOG¼Eastern Cooperative Oncology Group.
aGood-risk patients had a
performance status of 0 or 1 and normal serum lactate dehydrogenase (LDH)
levels; poor-risk patients had a performance status of X2 or elevated serum LDH
levels.
bGood-risk patients had a performance status of 0 and serum alkaline
phosphatase (ALP) levels of o1.25 normal range (N); intermediate-risk patients
had a performance status of X1 or serum ALP levels of X1.25 N; poor-risk
patients had a performance status of X1 and serum ALP levels of X1.25 N.
Table 2 Elevated serum tumour marker levels at diagnosis
Markers
Normal
range
No. of measured
patients
No. of
patients with
elevated levels (%)
AFP p10ngml
 1 42 2 (4.7)
b-HCG p0.5mIUml
 1 42 22 (52.4)
Cyfra p2.2ngml
 1 41 30 (73.2)
SCC p1.5ngml
 1 41 7 (17.1)
NSE p15ngml
 1 42 10 (23.8)
ProGRP o46pgml
 1 41 8 (19.5)
PSA p2.7ngml
 1 23 5 (21.7)
CEA p5.0ngml
 1 43 19 (44.2)
SLX p38Uml
 1 41 21 (51.2)
STN p45Uml
 1 41 16 (39)
NCC-ST439 p4.5Uml
 1 41 16 (39)
CA125 p35Uml
 1 39 25 (64.1)
CA15-3 p28Uml
 1 41 12 (29.3)
CA19-9 p37Uml
 1 43 17 (39.5)
PIVKA-II o40mIUml
 1 39 2 (5.1)
Elastase p300ngdl
 1 41 3 (7.3)
AFP¼a-fetoprotein; CA125¼carbohydrate antigen 125; CA15-3¼carbohydrate
antigen 15-3; CA19-9¼carbohydrate antigen 19-9; CEA¼carcinoembryonic
antigen; Cyfra¼cytokeratin 19 fragment; NCC-ST439¼national cancer center-
ST439; NSE¼neuron-specific antigen; PIVKA-II¼protein induced by vitamin K
absence-2; ProGRP¼progastrin-releasing peptide; PSA¼prostate-specific antigen;
SCC¼squamous-cell carcinoma antigen; SLX¼sialyl-specific embryonic antigen;
STN¼sialyl TN antigen; b-HCG¼b-human chorionic gonadotropin.
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smonths (Table 4). In two of these trials conducted to evaluate the
activity of first-line platinum-based combination chemotherapy,
the treatment regimen included irinotecan (Culine et al, 2003;
Briasoulis et al, 2008a). According to one, the combination of
irinotecan plus cisplatin yielded an objective response rate of 38%
and median OS of 6 months (Culine et al, 2003). In another study
limited to poor-prognosis patients, irinotecan plus oxaliplatin
yielded an objective response rate of 13% and median survival
time of 9.5 months, with 40% of the patients still alive at 1 year
(Briasoulis et al, 2008a). The patient background, especially the
prognostic characteristics, may have an influence on the treatment
outcome. Two-thirds of the patients in this study were prognos-
tically good-risk patients, with a low percentage of patients having
liver metastasis and a large percentage of patients with the disease
extent being limited to the lymph nodes; in contrast, in most of the
recently published series, the majority of the patients were
prognostically poor-risk patients and/or had liver metastasis.
Therefore, potential bias would make a reliable comparison of the
results of the present and previous studies difficult.
Interestingly, the Kaplan–Meier analysis in this study revealed a
2-year survival rate of 27%, with some patients even showing long-
term survival (Figure 1). The results of chemotherapy in a total of
1515 patients enrolled in 45 trials including 10 patients or more
conducted between 1964 and 2002 showed that survival of the
patients beyond 2 years was rare and that there were no cases of
disease-free survival beyond 3 years (Pavlidis et al, 2003; Greco
and Hainsworth, 2008). However, more recent studies have
reported long-term survival in a small percentage of patients
(Table 4). Long-term follow-up of the 396 patients enrolled in the
five most recent studies revealed 1-, 2-, 3-, 5-, 8- and 10-year
survival rates of 38, 19, 12, 11, 8 and 8% (Greco and Hainsworth,
2008). Although the reasons for the recent increase in long-term
survival are uncertain, it is noteworthy that long-term survival was
obtained with the combination of platinum agents and new agents.
The emergence of new non-platinum agents after 1995,
including taxanes, gemcitabine, vinorelbine and irinotecan,
has enabled the development of platinum-based combination
chemotherapy for patients with CUP (Pavlidis et al, 2003).
However, no definitive conclusions have been reached, because
there is still no evidence based on randomised clinical trials to
prove the superiority of the aforementioned combination
chemotherapies over single-agent platinum therapy. In addition,
the clinical benefits and risks of doublet and triplet combination
chemotherapies are still uncertain. An attempt was made by
European investigators to compare the effect of single-agent
cisplatin with that of combined therapy with gemcitabine plus
cisplatin on survival in good-risk patients with CUP. Although the
results of this prospective trial were expected to clarify the role of
combination chemotherapy in good-risk patients with CUP, the
trial was stopped due to insufficient accrual, and the result showed
a non-significantly higher survival with gemcitabine plus cisplatin
as compared to that with cisplatin alone (Gross-Goupil et al, 2008).
Recently, standard chemotherapeutic regimens with or without
molecular-targeting agents have been established for many
cancers. Thus, there is a great demand to optimise the
chemotherapeutic regimen for each patient with CUP. The
approach based on the genomic characteristics may come to
represent one of the breakthroughs in the proper use of
chemotherapies tailored to individual patients.
In addition, the advances in the development of many
molecular-targeted agents provide opportunities to explore various
new combination therapies containing both cytotoxic and
molecular-targeted agents for patients with CUP. Several studies
have demonstrated the immunohistochemical expression of
relevant molecular targets at high frequencies in tissue specimens
(Massard et al, 2007). A phase II trial of bevacizumab plus
erlotinib revealed substantial activity of this combination in
patients treated previously or patients who had not received
treatment because of the presence of poor-prognostic features
(Hainsworth et al, 2007). In a preliminary study, treatment with
paclitaxel plus carboplatin used in combination with bevacizumab
plus erlotinib yielded an objective response rate of 48% (N¼19
out of 40) and was well tolerated as first-line chemotherapy for
patients with CUP (Greco et al, 2008). After first-line platinum-
based combination chemotherapy, the approach of empiric
second-line chemotherapy has shown little promise, with extre-
mely low response rates (Hainsworth et al, 2001, 2005). Therefore,
tailor-made first-line chemotherapy by genomic typing or addition
of molecular-targeted drugs may be important in the treatment of
CUP, which includes heterogeneous cancers, rather than the
development of second-line chemotherapy.
In this study, the most frequently encountered toxicity was
haematological toxicity and some patients needed blood transfusion
or dose reduction of carboplatin. The dose delivery was fairly
smooth in the chemotherapy-naive patients with CUP as compared
with that in our earlier phase I study of combined irinotecan plus
carboplatin in patients with heavily treated ovarian cancer
(Yonemori et al, 2005). Among the advantages of this regimen are
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Figure 1 Kaplan–Meier analysis to determine the time to progression
(dotted line) and overall survival (solid line).
Table 3 Toxicity profiles (frequency410%)
Profile
Frequency
(%)
No. of
grade 3 (%)
No. of
grade 4 (%)
Haematologic toxicity
Leukopaenia 75.6 6 (13.3) 4 (8)
Neutropaenia 80 6 (13.3) 9 (20)
Anaemia 93.3 8 (17.8) 3 (6.7)
Thrombocytopaenia 68.9 7 (15.6) 2 (4.4)
Non-haematologic toxicity
Fatigue 60 0 (0) 0 (0)
Appetite loss 46.7 0 (0) 0 (0)
Nausea 82.2 1 (2.2) 0 (0)
Vomiting 26.7 1 (2.2) 0 (0)
Diarrhoea 57.8 4 (8) 0 (0)
Constipation 42.2 0 (0) 0 (0)
Skin rash 20 0 (0) 0 (0)
Febrile neutropaenia 13.3 5 (11.1) 1 (2.2)
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chemotherapy cycle according to the individual toxicity
profiles and to manage the chemotherapy on an outpatient basis
without prophylactic use of granulocyte-stimulating factor or
erythropoietin.
In conclusion, combined irinotecan plus carboplatin chemother-
apy appears to exert satisfactory activity and to be reasonably well
tolerated in patients with CUP. Many conventional chemotherapies
have been reported as the community standard of care for patients
with CUP. This regimen was moderately well tolerated and may
become established as one of the treatment options in patients
with a good PS.
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B¼bleomycin; Bv¼bevacizumab; Cape¼capecitabine; Carbo¼carboplatin; Cis¼cisplatin; Cy¼cyclophosphamide; D¼docetaxel; Dx¼doxorubicin; E¼etoposide;
Ep¼epirubicin; Er¼erlotinib; F¼5-FU; G¼gemcitabine; I¼ifosfamide; Ir¼irinotecan; m¼months; Mit¼mitomycin C; MST¼median survival time; NA¼not available;
Ox¼oxaliplatin; P¼paclitaxel; RR¼response rate; V¼vinorelbine.
a1 year¼1-year survival rate.
b2 year¼2-year survival rate.
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